Class / Patent application number | Description | Number of patent applications / Date published |
514162000 | With organic nitrogen containing compound | 53 |
20080227757 | Formulation for dermal application - The present invention relates to formulations on an aqueous basis with polyetherpolyol, dimethyl isosorbide, lipid and alcohol content suitable for penetration reinforcement of pharmaceutical active ingredients in the dermal application. The pharmaceutical active ingredients can be amphiphilic, zwitterionic, strongly polar or lipophilic. A preferred active ingredient is 5-aminolevulinic acid. | 09-18-2008 |
20080280858 | METHOD OF CREATING CRYSTALLINE SUBSTANCES - Process for preparing a cocrystal of an active substance and a cocrystal former, the process involving precipitating the active substance and the cocrystal former together from solution or suspension, in the presence of a supercritical or near-critical fluid, in particular using a GAS, SAS, SEDS or SAS-EM process. The invention also provides a cocrystal prepared using such a process, and its use as a seed crystal in a subsequent process for precipitating a cocrystal of an active substance and a cocrystal former. | 11-13-2008 |
20090029952 | UNIQUE COMBINATION OF ACETYLSALICYLIC ACID, ETHYLENEDIAMINE DIHYDROIODIDE (EDDI), AND BUFFER FOR USE IN ANIMAL DRINKING WATER - A unique combinations include acetylsalicylic acid (aspirin), ethylenediamine dihydriodide (EDDI), potassium iodide, sodium acetate, and sodium diacetate, useful in helping poultry, swine, and cattle overcome certain symptoms after vaccination. The inventive combinations readily dissolve in water at room temperature to form an effective concentration for inclusion in the animal's drinking water. | 01-29-2009 |
20090075951 | Methods and Reagents for the Treatment of Inflammatory Disorders - The invention features a method for treating a patient diagnosed with, or at risk of developing, an immunoinflammatory disorder by administering a tricyclic compound and, optionally, a corticosteroid or other compound to the patient. The invention also features a pharmaceutical composition containing a tricyclic compound and a corticosteroid or other compound for the treatment or prevention of an immunoinflammatory disorder. | 03-19-2009 |
20090099138 | PHARMACEUTICAL COMBINATION - A combination comprising as components (a) the compound 3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)-phenol, and (b) one or more non-steroidal anti-inflammatory drugs (NSAIDs); a pharmaceutical salt comprising said components; a compound derived from said components; a pharmaceutical formulation and a dosage form comprising said combination, salt, or compound; as well as a method of treating pain, e.g. chronic or acute pain, in a mammal characterized in that components (a) and (b) are administered simultaneously or sequentially to a mammal, wherein component (a) may be administered before or after component (b) and wherein components (a) or (b) are administered to the mammal either via the same or a different pathway of administration. | 04-16-2009 |
20090118242 | Injectable capsaicin with non-steroidal anti-inflammatory adjunctive agent - Disclosed in certain embodiments is a method for relieving pain at a site in a human or animal in need thereof, comprising administering by injection or infiltration, a dose of a capsaicinoid and coadministering an effective amount of a NSAID to decrease an undesired effect of the capsaicinoid. | 05-07-2009 |
20090192124 | USE OF CERAMIDES FOR DEPIGMENTING THE SKIN - The invention relates to the use, as agent for depigmenting and/or whitening the skin, in particular for eliminating pigmentary spots and/or senescence spots, and/or as anti-browning agents, of a compound of formula (I): | 07-30-2009 |
20090192125 | Local anti-infective agent for treatment of nail fungal infections - A topical composition for treating nail fungal infections that utilizes an acidic antifungal agent with a molecular weight no greater than 170 Daltons in a formulation having a pH less than or equal to the pKa of the acidic antifungal agent plus one. Possible antifungal agents include omadine, octanoic acid, sorbic acid, hexanoic acid, and benzoic acid. The antifungal agent can be combined with a delivery system such as a lacquer, a gel, a patch, or a hydrating system. A second therapeutic agent such as a 5-fluorocystine or terbinafine can be included. | 07-30-2009 |
20090221536 | TRANSDERMAL DELIVERY OF BENEFICIAL SUBSTANCES EFFECTED BY A HOSTILE BIOPHYSICAL ENVIRONMENT - The present invention generally relates to the transdermal delivery of substances and, in some embodiments, to the transdermal delivery of beneficial substances by a hostile biophysical environment. In one aspect, various methods for the transdermal delivery of beneficial substances are disclosed. By creating a hostile biophysical environment, beneficial substances may be delivered, according to certain embodiments, through the stratum corneum of the skin into the body. Beneficial substances include, but are not limited to, pharmaceutical agents, drugs, vitamins, co-factors, peptides, dietary supplements, and others. The beneficial effects disclosed include, for instance, relief of pain and inflammation, prevention and healing of ulcers of the skin, relief of headache, improved sexual function and enjoyment, growth of hair on the scalp, improving muscle size and/or function, removing body fat and/or cellulite, treating cancer, treating viral infections and others. A hostile biophysical environment may also be used in conjunction with systems and methods for increasing local blood flow, according to one set of embodiments. For example, by using a nitric oxide donor such as L-arginine, local blood flow may be increased, e.g., by transdermally delivering the nitric oxide precursor. The nitric oxide donor may be the sole cause of increased blood flow, or it may be supplemented with an adjunct such as theophylline. | 09-03-2009 |
20090258844 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISORDERS OF THE CENTRAL AND PERIPHERAL NERVOUS SYSTEMS - The present invention relates to methods and compositions for treating selected conditions of the central and peripheral nervous systems employing non-synaptic mechanisms. More specifically, one aspect of the present invention relates to methods and materials for treating seizure and seizure disorders, epilepsy, status epilepticus, migraine, spreading depression, intracranial hypertension; for treating the pathophysiological effects of head trauma, stroke, ischemia and hypoxia; for treating or protecting from the pathophysiological effects of neurotoxic agents such as ethanol; and for treating neuropsychiatric disorders and central nervous system edema by administering agents that modulate ionic concentrations and/or ionic gradients in the brain, particularly ion-dependent or cation-chloride cotransporter antagonists. Electrolyte cotransport antagonists and combinations of such compositions with other agents for treating various conditions are disclosed. | 10-15-2009 |
20100113402 | COMPOSITIONS FOR TREATMENT OF INFLAMMATORY DISEASES - Inflammatory bowel diseases are represented by two idiopathic disorders, which include ulcerative colitis and Crohn's disease. Ulcerative colitis is restricted to the colon and involves uncertain and inflammation of the lining (mucosa) of the large intestine. Crohn's disease, on the other hand, can involve the mucosa of the small and/or large intestine and may involve deeper layers of the bowel wall. The present invention is a combination of 5-aminosalicylic acid and one or more antioxidants (e.g., N-acetylcysteine) for treating such inflammatory bowel diseases. | 05-06-2010 |
20100120726 | 1-Methylnicotinamide Derivatives and Formulations of Treatment of Lipoprotein Abnormalities - The present invention is directed to nicotinamide derivatives, and their use in treating lipoprotein abnormalities, alone or in combination with a statin. | 05-13-2010 |
20100144682 | COMPOSITION BASED ON SALICYLIC ACID DERIVATIVES - The present invention relates to an aqueous composition for topical application comprising at least one (C | 06-10-2010 |
20100249080 | PERSONAL CARE COMPOSITION - A personal care composition comprising a eutectic mixture, the eutectic mixture comprising a CB receptor activating agent, in which the CB receptor is preferably palmitoylethanolamide. A method of mitigating scalp itch. | 09-30-2010 |
20100286099 | INTRAVENOUS FORMULATION WITH WATER-SOLUBLE COCRYSTALS OF ACETYLSALICYLIC ACID AND THEANINE - A water-soluble aspirin-theanine cocrystal composition which includes a quantity of acetylsalicylic acid and a quantity of a theanine enantiomer associated with the quantity of acetylsalicylic acid. The composition may be created by a method including the steps of: (i) providing a quantity of acetylsalicylic acid; (ii) adding a quantity of a theanine enantiomer to the quantity of acetylsalicylic acid to form a mixture comprising the quantity of acetylsalicylic acid and the enantiomer of theanine; (iii) wetting the mixture; and (iv) grinding the mixture for a length of time sufficient to produce a dried crystalline mass. The water-soluble cocrystal composition is suitable for intravenous administration, preferably to humans. | 11-11-2010 |
20100323995 | COMPOUNDS, COMPOSITIONS AND METHODS FOR PREVENTING NEURODEGENERATION IN ACUTE AND CHRONIC INJURIES IN THE CENTRAL NERVOUS SYSTEM - The present invention provides compositions and methods for prevention and prophylaxis of neurological diseases accompanied by neuronal death. The invention includes synthesis of 5-benzylamino salicylic acid (BAS) and its derivatives. BAS and its derivatives protect cortical neurons from toxic insults by N-methyl-D-aspartate, Zn | 12-23-2010 |
20110065677 | Methods of Treating Inflammation with Compositions Comprising Lecithin Oils and NSAIDS for Protecting the Gastrointestinal Tract and Providing Enhanced Therapeutic Activity - A novel pharmaceutical composition is provided by which nonsteroidal anti-inflammatory drugs (NSAIDs) are added directly to phospholipid-containing oil such as lecithin oils or to a bio-compatible oil to which an phospholipid has been added to make a NSAID-containing formulation that possess low gastrointestinal (GI) toxicity and enhanced therapeutic activity to treat or prevent inflammation, pain, fever, platelet aggregation, tissue ulcerations and/or other tissue disorders. The composition of the invention are in the form of a non-aqueous solution, paste, suspension, dispersion, colloidal suspension or in the form of an aqueous emulsion or microemulsion for internal, oral, direct or topical administration. | 03-17-2011 |
20110071118 | Methods of Making Compositions Comprising Lecithin Oils and NSAIDS for Protecting the Gastointestinal Tract and Providing Enhanced Therapeuitc Activity - A novel pharmaceutical composition is provided by which nonsteroidal anti-inflammatory drugs (NSAIDs) are added directly to phospholipid-containing oil such as lecithin oils or to a bio-compatible oil to which an phospholipid has been added to make a NSAID-containing formulation that possess low gastrointestinal (GI) toxicity and enhanced therapeutic activity to treat or prevent inflammation, pain, fever, platelet aggregation, tissue ulcerations and/or other tissue disorders. The composition of the invention are in the form of a non-aqueous solution, paste, suspension, dispersion, colloidal suspension or in the form of an aqueous emulsion or microemulstion for internal, oral, direct or topical administration. | 03-24-2011 |
20110251161 | PERSONAL CARE COMPOSITION - A personal care composition comprising a eutectic mixture, the eutectic mixture comprising an alkyl monoethanolamide having an alky chain length from 10 to 14. | 10-13-2011 |
20120077784 | SKIN TREATMENT COMPOSITIONS - The present invention relates to compositions, kits and methods for treating skin at sites of concerns such as infectious lesions and/or points of insertion of an insertable medical device to prevent contamination such as infections or protein absorption that may interfere with the function of the device. The composition can be a topical skin treatment composition that includes polyethylene glycol (PEG), triclosan, one or more of a salicylate, bronopol, and an acrylic emulsion, and, optionally, a solvent. | 03-29-2012 |
20120149666 | COMPOSITIONS AND METHODS OF TREATMENT FOR INFLAMMATORY DISEASES - Inflammatory bowel diseases are represented by two idiopathic disorders, which include ulcerative colitis and Crohn's disease. Ulcerative colitis is restricted to the colon and involves uncertain and inflammation of the lining (mucosa) of the large intestine. Crohn's disease, on the other hand, can involve the mucosa of the small and/or large intestine and may involve deeper layers of the bowel wall. The present invention is a combination of 5-aminosalicylic acid and one or more antioxidants (e.g., N-acetylcysteine) for treating such inflammatory bowel diseases. | 06-14-2012 |
20120184513 | Organic Compounds - The invention relates to organic compounds having the ability to reduce or suppress the onset of skin irritation induced by extraneous cause selected from the group of 2-heptylcyclopentanone, 2-ethoxynaphthalene; 2-methoxynaphthalene; 1-methoxy-4-(prop-1-enyl)benzene; 1-(cyclopropylmethyl)-4-methoxybenzene; | 07-19-2012 |
20120190655 | Intravenous Formulation with Water-Soluble CoCrystals of Acetylsalicylic Acid and Theanine - An aspirin-theanine cocrystal composition including a quantity of acetylsalicylic acid and a quantity of a theanine enantiomer combined with the quantity of acetylsalicylic acid in a mixture. The theanine enantiomer may be L-theanine, D-theanine, or DL-theanine | 07-26-2012 |
20120214772 | COMPOSITIONS FOR TREATMENT OF INFLAMMATORY DISEASES - Inflammatory bowel diseases are represented by two idiopathic disorders, which include ulcerative colitis and Crohn's disease. Ulcerative colitis is restricted to the colon and involves uncertain and inflammation of the lining (mucosa) of the large intestine. Crohn's disease, on the other hand, can involve the mucosa of the small and/or large intestine and may involve deeper layers of the bowel wall. The present invention is a combination of 5-aminosalicylic acid and one or more antioxidants (e.g., N-acetylcysteine) for treating such inflammatory bowel diseases. | 08-23-2012 |
20120302528 | BIOABSORBABLE POLYMER COMPOSITIONS EXHIBITING ENHANCED CRYSTALLIZATION AND HYDROLYSIS RATES - A bimodal bioabsorbable polymer composition. The composition includes a first amount of a bioabsorbable polymer polymerized so as to have a first molecular weight distribution; a second amount of said bioabsorbable polymer polymerized so as to have a second molecular weight distribution having a weight average molecular weight between about 10,000 to about 50,000 Daltons, the weight average molecular weight ratio of said first molecular weight distribution to said second molecular weight distribution is at least about two to one; wherein a substantially homogeneous blend of said first and second amounts of said bioabsorbable polymer is formed in a ratio of between about 50/50 to about 95/5 weight/weight percent. Also disclosed are a medical device, a method of making a medical device and a method of melt blowing a semi-crystalline polymer blend. | 11-29-2012 |
20130012482 | INTRAVENOUS FORMULATION WITH WATER-SOLUBLE COCRYSTALS OF ACETYLSALICYLIC ACID AND THEANINE - A water-soluble cocrystal composition contains a quantity of acetylsalicylic acid and a quantity of a theanine enantiomer selected from an alpha variant of theanine or a beta variant of theanine or other form of theanine. | 01-10-2013 |
20130096093 | COMPOSITIONS AND METHODS OF TREATMENT FOR INFLAMMATORY DISEASES - Inflammatory bowel diseases are represented by two idiopathic disorders, which include ulcerative colitis and Crohn's disease. Ulcerative colitis is restricted to the colon and involves uncertain and inflammation of the lining (mucosa) of the large intestine. Crohn's disease, on the other hand, can involve the mucosa of the small and/or large intestine and may involve deeper layers of the bowel wall. The present invention is a combination of 5-aminosalicylic acid and one or more antioxidants (e.g., N-acetylcysteine) for treating such inflammatory bowel diseases. | 04-18-2013 |
20130123218 | Intravenous Formulation with Water-soluble CoCrystals of Acetylsalicylic Acid and Theanine - A method of treatment using a water-soluble cocrystal composition contains a quantity of acetylsalicylic acid and a quantity of a theanine enantiomer selected from an alpha variant of theanine or a beta variant of theanine or other form of theanine. | 05-16-2013 |
20130225538 | BIOABSORBABLE POLYMER COMPOSITIONS EXHIBITING ENHANCED CRYSTALLIZATION AND HYDROLYSIS RATES - A bimodal bioabsorbable polymer composition. The composition includes a first amount of a bioabsorbable polymer polymerized so as to have a first molecular weight distribution; a second amount of said bioabsorbable polymer polymerized so as to have a second molecular weight distribution having a weight average molecular weight between about 10,000 to about 50,000 Daltons, the weight average molecular weight ratio of said first molecular weight distribution to said second molecular weight distribution is at least about two to one; wherein a substantially homogeneous blend of said first and second amounts of said bioabsorbable polymer is formed in a ratio of between about 50/50 to about 95/5 weight/weight percent. Also disclosed are a medical device, a method of making a medical device and a method of melt blowing a semi-crystalline polymer blend. | 08-29-2013 |
20130252925 | PAIN RELIEF COMPOSITIONS, MANUFACTURE AND USES - The present invention relates to TRPV1 selective agonist topical compositions including capsaicinoid and analgesic agent compositions and methods of manufacture and methods of providing pain relief as well as treating a variety of disorders with such compositions. | 09-26-2013 |
20130261091 | Salicylic Acid Gel - A concentrated salicylic acid gel comprising salicylic acid and a stabilizer compound, wherein the salicylic acid comprises at least 30 wt % of the total weight of the gel. | 10-03-2013 |
20130345183 | INTRAVENOUS FORMULATION WITH WATER-SOLUBLE COCRYSTALS OF ACETYLSALICYLIC ACID AND THEANINE - A method of treating rheumatoid arthritis using a water-soluble cocrystal composition contains a quantity of acetylsalicylic acid and a quantity of a theanine enantiomer selected from an alpha variant of theanine or a beta variant of theanine or other form of theanine. | 12-26-2013 |
20140073612 | TRANSDERMAL DELIVERY SYSTEM KIT - A transdermal delivery kit that enhances the efficacy of a topical drug includes at least one drug dispensing device, a lipophilic base, a hydrophilic base, a lipid-soluble active ingredient, a water-soluble active ingredient, a first container for mixing the lipophilic base with the lipid-soluble active ingredient to form a first compound, a second container for mixing the hydrophilic base with the water-soluble active ingredient to form a second compound, a mixing member, and instructions for compounding the lipophilic base with the lipid-soluble active ingredient to form the first compound, compounding the hydrophilic base with the water-soluble active ingredient to form the second compound, and mixing the first compound and the second compound to form a transdermal pharmaceutical delivery system capable of delivering a drug to the dermal layer of the skin. | 03-13-2014 |
20140073613 | TOPICAL FORMULATION FOR TREATMENT OF HYPERKERATOTIC SKIN - The present invention relates in general to topical compositions having improved antimicrobial effect useful for the treatment of hyperkeratotic skin conditions. More specifically, the present invention relates to topical compositions comprising a combination of one or more alfa-hydroxy acids, urea, glycerol, and panthenol, as well as the use of such compositions for the treatment of hyperkeratotic skin conditions, in particular on the feet, and also on other body areas where thick skin is noted and where infections should be avoided. | 03-13-2014 |
20140148418 | INTRAVENOUS FORMULATION WITH WATER-SOLUBLE COCRYSTALS OF ACETYLSALICYLIC ACID AND THEANINE - A method of treating high grade temperature using a water-soluble cocrystal composition contains a quantity of acetylsalicylic acid and a quantity of a theanine enantiomer selected from an alpha variant of theanine or a beta variant of theanine or other form of theanine. | 05-29-2014 |
20140179643 | PLOD-2 Stimulators and Their Use in the Treatment of Skin - Methods for preventing, ameliorating, or reducing dermatological signs of aging are provided which employ a composition comprising an effective amount of N-Acetyl-Tyrosinamide and an effective amount of a retinoid, in a cosmetically acceptable vehicle, for topical application to the skin for a time sufficient to improve the appearance of said skin. | 06-26-2014 |
20140179644 | INTRAVENOUS FORMULATION WITH WATER-SOLUBLE COCRYSTALS OF ACETYLSALICYLIC ACID AND THEANINE - A method of reducing hepatocellular damage in a subject using a water-soluble cocrystal composition which contains a quantity of acetylsalicylic acid and a quantity of a theanine enantiomer. | 06-26-2014 |
20140235594 | INTRAVENOUS FORMULATION WITH WATER-SOLUBLE COCRYSTALS OF ACETYLSALICYLIC ACID AND THEANINE - A method of treating a condition associated with excess gluatame in a subject using a water-soluble cocrystal composition which contains a quantity of acetylsalicylic acid and a quantity of a theanine enantiomer. | 08-21-2014 |
20140288029 | INTRAVENOUS FORMULATION WITH WATER-SOLUBLE COCRYSTALS OF ACETYLSALICYLIC ACID AND THEANINE - A method of treating myocardial infarction in a subject using a water-soluble cocrystal composition which contains a quantity of acetylsalicylic acid and a quantity of a theanine enantiomer. | 09-25-2014 |
20140296189 | INTRAVENOUS FORMULATION WITH WATER-SOLUBLE COCRYSTALS OF ACETYLSALICYLIC ACID AND THEANINE - A method of reducing niacin flushing in a subject using a water-soluble cocrystal composition which contains a quantity of acetylsalicylic acid and a quantity of a theanine enantiomer. | 10-02-2014 |
20140323445 | Salicylic Acid Gel - A salicylic acid gel contains salicylic acid, a thickener, and a stabilizer compound. The gel may be diluted and/or incorporated into final skin care products. | 10-30-2014 |
20140343021 | ADJUVANT TO THROMBOLYTIC THERAPY FOR THE TREATMENT OF FROSTBITE - A method of treating frostbite in a subject using a water-soluble cocrystal composition which contains a quantity of acetylsalicylic acid and a quantity of a theanine enantiomer. | 11-20-2014 |
20140349978 | Salicylic Acid Gel - A concentrated salicylic acid gel comprising salicylic acid and a stabilizer compound, wherein the salicylic acid comprises at least 30 wt % of the total weight of the gel. | 11-27-2014 |
20140357602 | Combination Therapies For Treating Metabolic Disorders - This invention is directed to pharmaceutical combinations comprising an antioxidant agent, an anti-inflammatory agent, and optionally at least one other anti-diabetic agent useful for treating metabolic disorders. This invention also encompasses pharmaceutically acceptable compositions comprising an antioxidant agent, an anti-inflammatory agent, optionally at least one other anti-diabetic agent, and at least one pharmaceutically acceptable carrier. The combinations and compositions of this invention are useful as methods for treating metabolic disorders including diabetes, particularly Type I and Type II diabetes, as well as diseases and disorders associated with diabetes, including but not limited to atherosclerosis, cardiovascular disease, inflammatory disorders, nephropathy, neuropathy, retinopathy, β-cell dysfunction, dyslipidemia, LADA, metabolic syndrome, hyperglycemia, insulin resistance, and/or chronic obstructive pulmonary disease in a mammal, particularly a diabetic mammal, and specifically a human patient. This invention is particularly directed to pharmaceutical compositions comprising an lipoic acid, one or more anti-inflammatories selected from the group consisting of diflunisal, diclofenac, dexibuprofen, dexketoprofen, naproxen, and salicylate, and optionally one or more pharmaceutically acceptable carriers. The compositions of this invention are useful as methods for treating metabolic disorders including type II diabetes, insulin resistance, beta-cell dysfunction, and hyperglycemia in a patient, particularly a diabetic patient. | 12-04-2014 |
20150133407 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF RESPIRATORY DISORDERS - The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of respiratory disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of viscid or excessive mucus, cough, inflammation, redness in sore throat, infection in the throat, sore throat, abnormal mucus secretion, impaired mucus transport, allergic rhinitis, asthma, COPD, respiratory muscular disorders and pain in acute sore throat. | 05-14-2015 |
20150133408 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF RESTLESS LEG SYNDROME AND FIBROMYALGIA - The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of fibromyalgia, restless leg syndrome may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of motor neurone disease, diabetic neuropathy, postherpetic neuralgia, acute opioid withdrawal management, obsessive-compulsive disorder, premature ejaculation, PTSD, injury, post-operative pain, osteoarthritis, rheumatoid arthritis, multiple sclerosis, spinal cord injury, migraine, HIV related neuropathic pain, bipolar depression, depression, stress, cancer pain and lower back pain. | 05-14-2015 |
20150290151 | TOPICAL COMPOSITIONS FOR PAIN RELIEF, MANUFACTURE AND USE - The present invention relates to TRPV1 selective agonist compositions including a capsaicinoid, a surfactant and an extended release agent, and to methods of manufacture and methods of providing pain relief as well as treating a variety of disorders with such compositions. | 10-15-2015 |
20150342905 | Methods for Overcoming Resistance to Tramadol - There is disclosed a method for treating disorders modulated by at least opiate receptor activity or monoamine activity, including acute and chronic pain, comprising administering a pharmaceutical formulation comprising O-desmethyltramadol. Methods are also provided that are effective for overcoming resistance to tramadol in patients. | 12-03-2015 |
20150342912 | METHOD AND FORMULATION FOR TREATING MUCOSAL DISCONTINUITIES AND FOR REDUCING BIOFILMS - A gelled formulation suitable for use in the treatment of discontinuities, comprising: phenolsulfonic acid in a concentration of 25-80% by weight; guaiacolsulfonic acid in a concentration of 25-80% by weight; free sulfuric acid in a concentration of 0 to 32% by weight; and water in a concentration of 0 to 3% by weight diluted in a gel comprising colloidal silica to a concentration of 2 to 5% by weight of the gel. | 12-03-2015 |
20160015633 | XYLITOL CONTAINING COMESTIBLE PRODUCT - The present invention relates to a process for preparing a comestible product comprising xylitol said method comprising: (a) subjecting a composition comprising xylitol in an amount ranging from about 60% to about 100% by weight to extrusion treatment inside an extrusion apparatus under conditions sufficient to form and maintain the xylitol in a slurry and (b) then shaping the extruded slurry and cooling the product to form a solid. The present invention additionally is directed to a product produced therefrom. | 01-21-2016 |
20160106690 | PAIN RELIEF COMPOSITIONS, MANUFACTURE AND USES - The present invention relates to TRPV1 selective agonist topical compositions including capsaicinoid and analgesic agent compositions and methods of manufacture and methods of providing pain relief as well as treating a variety of disorders with such compositions. | 04-21-2016 |
20160151280 | Enhanced Stability of Novel Liquid Compositions | 06-02-2016 |
20160175330 | METHOD OF TREATMENT USING AN ASSOCIATION OF LOSARTAN AND ACETYLSALICYLIC ACID, AND KIT | 06-23-2016 |